FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 346:381-382 January 31, 2002 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Several important issues were overlooked in the Case Record of the 14-year-old boy with oncogenic hypophosphatemic osteomalacia (Sept. 20 issue).¹ Terek was correct in stating that oncogenic hypophosphatemic osteomalacia has many similarities to X-linked hypophosphatemia. However, the onset of hypophosphatemia is not delayed in X-linked hypophosphatemia. Terek did not consider a diagnosis of autosomal dominant hypophosphatemic rickets, which has incomplete penetrance and a variable age of onset.² Therefore, an affected child's parent may carry a mutation for autosomal dominant hypophosphatemic rickets that is nonpenetrant, and the child may have delayed phosphate wasting. It is important to note . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Larsson, T., Marsell, R., Schipani, E., Ohlsson, C., Ljunggren, O., Tenenhouse, H. S., Juppner, H., Jonsson, K. B. (2004). Transgenic Mice Expressing Fibroblast Growth Factor 23 under the Control of the {alpha}1(I) Collagen Promoter Exhibit Growth Retardation, Osteomalacia, and Disturbed Phosphate Homeostasis. Endocrinology 145: 3087-3094 [Abstract] [Full Text]